Fabrizio Martora (F Martora)

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 178

Top Venues

Clinical and experimental dermatology

Clinical, cosmetic and investigational dermatology

Journal of the European Academy of Dermatology and Venereology : JEADV

Journal of cosmetic dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Fabrizio Martora, Claudio Marasca, Sara Cacciapuoti, Federica Fariello, Luca Potestio, Teresa Battista, Massimiliano Scalvenzi, Matteo Megna
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Fabrizio Martora, Teresa Battista, Luca Potestio, Antonio Portarapillo, Nello Tommasino, Matteo Megna
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Matteo Megna, Ruggiero Angelo, Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Massimiliano Scalvenzi, Aimillios Lallas, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Laura Marano, Alessia Villani
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation. Cancers 16 (9) (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy 25 (9) (2024)
Alessia Villani, Luca Potestio, Aimilios Lallas, Zoe Apalla, Massimiliano Scalvenzi, Fabrizio Martora
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? Medicina (Kaunas, Lithuania) 60 (6) (2024)
Giuseppe Lauletta, Fabrizio Martora, Francesca di Vico, Cataldo Patruno, Maddalena Napolitano
Effectiveness, Safety, and Long-Term Continuation Rate Analysis of Dupilumab Treatment in Adolescents with Atopic Dermatitis: A Single-Center Real-Life Retrospective Study. Dermatitis : contact, atopic, occupational, drug (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety (2024)
Fabrizio Martora, Matteo Megna, Teresa Battista, Massimiliano Scalvenzi, Alessia Villani, Sara Cacciapuoti, Luca Potestio
Viral reactivation following COVID-19 vaccination: a review of the current literature. Clinical and experimental dermatology 49 (6) (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
Author Reply to "Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?" by Duff et al. Clinical and experimental dermatology (2024)
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, Alessia Villani, Fabrizio Martora, Ruggiero Angelo, Lucia Genco, Luca Potestio
The Past, the Present and the Future of Teledermatology: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy 25 (9) (2024)
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clinical, cosmetic and investigational dermatology 17 (2024)
Fabrizio Martora, Claudio Marasca, Sara Cacciapuoti, Federica Fariello, Luca Potestio, Teresa Battista, Massimiliano Scalvenzi, Matteo Megna
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Ruggiero Angelo, Matteo Megna
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Teresa Battista, Vincenzo Picone, Matteo Noto, Luca Potestio, Angelo Ruggiero, Fabrizio Martora, Matteo Megna, Lucia Genco
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert opinion on drug safety (2024)
Fabrizio Martora, Teresa Battista, Luca Potestio, Antonio Portarapillo, Nello Tommasino, Matteo Megna
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Teresa Battista, Vincenzo Picone, Matteo Noto, Luca Potestio, Angelo Ruggiero, Fabrizio Martora, Matteo Megna, Lucia Genco
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert opinion on drug safety (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Alessia Villani, Luca Potestio, Aimilios Lallas, Zoe Apalla, Massimiliano Scalvenzi, Fabrizio Martora
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? Medicina (Kaunas, Lithuania) 60 (6) (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Fabrizio Martora, Cataldo Patruno, Silvia D'Ascenzo, Maddalena Napolitano
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. The Journal of dermatological treatment 35 (1) (2024)
Matteo Megna, Ruggiero Angelo, Ginevra Torta, Fabrizio Martora, Mariateresa Bianco, Luca Potestio
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced. Clinical and experimental dermatology (2024)
Luca Potestio, Massimiliano Scalvenzi, Aimillios Lallas, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Laura Marano, Alessia Villani
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation. Cancers 16 (9) (2024)
Matteo Megna, Ruggiero Angelo, Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Tiziana Fioretti, Fabrizio Martora, Ilaria De Maggio, Adelaide Ambrosio, Carmelo Piscopo, Sabrina Vallone, Felice Amato, Diego Passaro, Fabio Acquaviva, Francesca Gaudiello, Daniela Di Girolamo, Valeria Maiolo, Federica Zarrilli, Speranza Esposito, Giuseppina Vitiello, Luigi Auricchio, Elena Sammarco, Daniele De Brasi, Roberta Petillo, Antonella Gambale, Fabio Cattaneo, Rosario Ammendola, Paola Nappa, Gabriella Esposito
Comprehensive Molecular Analysis of Disease-Related Genes as First-Tier Test for Early Diagnosis, Classification, and Management of Patients Affected by Nonsyndromic Ichthyosis. Biomedicines 12 (5) (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy (2024)
Fabrizio Martora, Cataldo Patruno, Silvia D'Ascenzo, Maddalena Napolitano
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. The Journal of dermatological treatment 35 (1) (2024)
Tiziana Fioretti, Fabrizio Martora, Ilaria De Maggio, Adelaide Ambrosio, Carmelo Piscopo, Sabrina Vallone, Felice Amato, Diego Passaro, Fabio Acquaviva, Francesca Gaudiello, Daniela Di Girolamo, Valeria Maiolo, Federica Zarrilli, Speranza Esposito, Giuseppina Vitiello, Luigi Auricchio, Elena Sammarco, Daniele De Brasi, Roberta Petillo, Antonella Gambale, Fabio Cattaneo, Rosario Ammendola, Paola Nappa, Gabriella Esposito
Comprehensive Molecular Analysis of Disease-Related Genes as First-Tier Test for Early Diagnosis, Classification, and Management of Patients Affected by Nonsyndromic Ichthyosis. Biomedicines 12 (5) (2024)
Luca Potestio, Giuseppe Lauletta, Nello Tommasino, Antonio Portarapillo, Antonia Salsano, Teresa Battista, Fabrizio Martora, Matteo Megna
Risk Factors for Psoriasis Flares: A Narrative Review. Psoriasis (Auckland, N.Z.) 14 (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Fabrizio Martora, Cataldo Patruno, Silvia D'Ascenzo, Maddalena Napolitano
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. The Journal of dermatological treatment 35 (1) (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
Author Reply to "Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?" by Daungsupawong et al. Clinical and experimental dermatology (2024)
Luca Potestio, Michela D'Agostino, Antonio Portarapillo, Valeria Esposito, Nello Tommasino, Antonia Salsano, Luigi Guerriero, Fabrizio Martora, Matteo Megna
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris. Life (Basel, Switzerland) 14 (8) (2024)
Antonio Portarapillo, Valeria Esposito, Matteo Megna, Luca Potestio, Rosita Comune, Fabrizio Martora, Ruggiero Angelo
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study. Clinical and experimental dermatology (2024)
Maddalena Napolitano, Fabrizio Martora, A Antelmi, Martin Mowitz, M Scalvenzi, T Battista, Cataldo Patruno
Allergic contact dermatitis to petrolatum: An unknown for patch testing. Contact dermatitis (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
ChatGPT and Medical Writing in Dermatology: why should we keep writing? Clinical and experimental dermatology (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Maddalena Napolitano, Fabrizio Martora, A Antelmi, Martin Mowitz, M Scalvenzi, T Battista, Cataldo Patruno
Allergic contact dermatitis to petrolatum: An unknown for patch testing. Contact dermatitis 90 (6) (2024)
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clinical, cosmetic and investigational dermatology 17 (2024)
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, Alessia Villani, Fabrizio Martora, Ruggiero Angelo, Lucia Genco, Luca Potestio
The Past, the Present and the Future of Teledermatology: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
ChatGPT and medical writing in dermatology: why should we keep writing? Clinical and experimental dermatology 49 (8) (2024)
Fabrizio Martora, Matteo Megna, Teresa Battista, Massimiliano Scalvenzi, Alessia Villani, Sara Cacciapuoti, Luca Potestio
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature. Clinical and experimental dermatology (2024)
Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Ruggiero Angelo, Matteo Megna
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Michela D'Agostino, Fabrizio Martora, Matteo Megna, Maddalena Napolitano, Luca Potestio
Lichen planus following Covid-19 vaccination: a narrative review. Clinical and experimental dermatology (2024)
Luca Potestio, Giuseppe Lauletta, Nello Tommasino, Antonio Portarapillo, Antonia Salsano, Teresa Battista, Fabrizio Martora, Matteo Megna
Risk Factors for Psoriasis Flares: A Narrative Review. Psoriasis (Auckland, N.Z.) 14 (2024)
Luca Potestio, Fabrizio Martora, Alessia Villani, Ruggiero Angelo, Massimiliano Scalvenzi, Matteo Megna
ChatGPT and Dermatology: friends or foes? Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Ruggiero Angelo, Matteo Megna
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. Clinical, cosmetic and investigational dermatology 16 (2023)
Luca Potestio, Fabrizio Martora, Alessia Villani, Sara Cacciapuoti, Teresa Battista, Matteo Megna
Advancing Dermatology: Embracing the Power of Artificial Intelligence. Clinical and experimental dermatology (2023)
Luca Potestio, Fabrizio Martora, Matteo Megna, Alessia Villani, Sara Cacciapuoti
Comment on 'Development of Chilblains Lesions During the COVID-19 Pandemic is Strongly Associated with Cold Weather: Retrospective Analysis of Patients from a Single Center in the United States'. Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora, Matteo Megna
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature. Psoriasis (Auckland, N.Z.) 13 (2023)
Fabrizio Martora, Paolo Ascierto, Marco Palla, Claudia Costa, Mirella D'Andrea, Rossella Di Trolio, Luigi Scarpato, Claudio Marasca
Tirbanibulin:An alternative topical approach to manage superficial Basal Cell Carcinoma. Clinical and experimental dermatology (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Luca Potestio, Alessia Villani, Flavia Raia, Gabriella Fabbrocini, Fabrizio Martora
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256". Journal of cosmetic dermatology 22 (3) (2023)
Luca Potestio, Massimiliano Scalvenzi, Fabrizio Martora, Luca Costanzo, Lucia Gallo
Comment on "Permethrin-unresponsive scabies in London, United Kingdom - a wake up call". Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luca Potestio, Fabrizio Martora, Alessia Villani, Matteo Megna, Ruggiero Angelo
Comment on: "Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination" by Gambichler. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Matteo Megna, Ruggiero Angelo, Antonia Salsano, Giuseppe Lauletta, Antonio Portarapillo, Ginevra Torta, Fabrizio Martora, Luca Potestio
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Luca Potestio
Comment on 'Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination'. Clinical and experimental dermatology 48 (1) (2023)
Luca Potestio, Alessia Villani, Flavia Raia, Gabriella Fabbrocini, Fabrizio Martora
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256". Journal of cosmetic dermatology 22 (3) (2023)
Luca Potestio, Matteo Megna, Alessia Villani, Sara Cacciapuoti, Massimiliano Scalvenzi, Fabrizio Martora
Herpes Zoster and COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 16 (2023)
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Angelo Ruggiero, Matteo Megna
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert opinion on drug safety (2023)
Luca Potestio, Ruggiero Angelo, Gabriella Fabbrocini, Fabrizio Martora, Luca Costanzo, Lucia Gallo
Reply to "oral ivermectin to treat scabies: a comparison of two different regimens". Clinical and experimental dermatology (2023)
Luca Potestio, Lucia Genco, Matteo Noto, Gabriella Fabbrocini, Teresa Battista, Fabrizio Martora
Comment on 'Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine'. Clinical and experimental dermatology 48 (1) (2023)
Luca Potestio, Alessia Villani, Flavia Raia, Gabriella Fabbrocini, Fabrizio Martora
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256". Journal of cosmetic dermatology (2023)
Fabrizio Martora, Claudio Marasca, Vincenzo Picone, Luigi Fornaro, Matteo Megna, Gabriella Fabbrocini
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis. Journal of clinical medicine 12 (3) (2023)
Fabrizio Martora, Matteo Megna, Teresa Battista, Luca Potestio, Maria Carmela Annunziata, Claudio Marasca, Alessia Villani, Gabriella Fabbrocini
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. Clinical, cosmetic and investigational dermatology 16 (2023)
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora, Matteo Megna
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature. Psoriasis (Auckland, N.Z.) 13 (2023)
Luca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, Fabrizio Martora, Ruggiero Angelo, Matteo Megna
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection. Clinical, cosmetic and investigational dermatology 16 (2023)
Luca Potestio, Lucia Genco, Teresa Battista, Matteo Noto, Gabriella Fabbrocini, Fabrizio Martora
Comment on 'Anogenital dermatology: challenges in the digital era'. Clinical and experimental dermatology 48 (1) (2023)
Fabrizio Martora, Alessia Villani, Claudio Marasca, Gabriella Fabbrocini, Ruggiero Angelo
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al. The Australasian journal of dermatology (2023)
Fabrizio Martora, Ruggiero Angelo, Teresa Battista, Luca Potestio, Matteo Megna
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." Clinical and experimental dermatology (2023)
Luca Potestio, Teresa Battista, Sara Cacciapuoti, Ruggiero Angelo, Fabrizio Martora, Luigi Fornaro, Elisa Camela, Matteo Megna
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge. Biomedicines 11 (8) (2023)
Giuseppe Monfrecola, Luigi Fornaro, Paolo Antonio Ascierto, Luigi Scarpato, Claudia Costa, Fabrizio Martora, Claudio Marasca
Comment on the relationship between wide tattoos and delayed melanoma diagnosis. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Fabrizio Martora, Alessia Villani, Claudio Marasca, Gabriella Fabbrocini, Ruggiero Angelo
Cutaneous adverse reaction following COVID-19 vaccination: Report from a southern Italian referral centre. Comment on "cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine" by Luo et al. The Australasian journal of dermatology 64 (1) (2023)
Luca Potestio, Lucia Genco, Teresa Battista, Matteo Noto, Gabriella Fabbrocini, Fabrizio Martora
Comment on 'Anogenital dermatology: challenges in the digital era'. Clinical and experimental dermatology 48 (1) (2023)
Fabrizio Martora, Gabriella Fabbrocini, Claudio Marasca, Teresa Battista, Matteo Megna
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab". Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Fabrizio Martora, Claudio Marasca, Vincenzo Picone, Luigi Fornaro, Matteo Megna, Gabriella Fabbrocini
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis. Journal of clinical medicine 12 (3) (2023)
Fabrizio Martora, Paolo Antonio Ascierto, Massimiliano Scalvenzi, Marco Palla, Claudia Costa, Mirella D'Andrea, Rossella Di Trolio, Luigi Scarpato, Claudio Marasca
Tirbanibulin ointment to manage recurrence of superficial Basal Cell Carcinoma of the face: report of a case. Clinical and experimental dermatology (2023)
Luca Potestio, Elisa Camela, Sara Cacciapuoti, Luigi Fornaro, Ruggiero Angelo, Fabrizio Martora, Teresa Battista, Matteo Megna
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19. Tropical medicine and infectious disease 8 (2) (2023)
Luca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, Fabrizio Martora, Ruggiero Angelo, Matteo Megna
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Matteo Megna
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19. Tropical medicine and infectious disease 8 (2) (2023)

Fabrizio Martora.css-eqlu8i{font-size:small;padding-left:4px;} (F Martora)

Publication Activity (10 Years)

Top Topics

Top Venues

Fabrizio Martora (F Martora)